Treatment of non-insulin-dependent diabetes mellitus

Bibliography

• WORLD HEALTH ORGANIZATION: Prevention of Diabetes Mellitus. (1994) (Report 884).
   Google Scholar
• WORLD HEALTH ORGANIZATION: Global burden of diabetes mellitus. (1998) (Press Release WH0/63).
   Google Scholar
• LIU KG, LAMBERT MH, AYSCUE AH et al.: Synthesis and biological activity if L-tyrosine-based PPARgamma agonists with reduced molecular weight. Bioorg. Med. Chem. Lett (2001) 11(24):3111–3113.
   PubMed Web of Science ®Google Scholar
• LIU KG, LAMBERT MH, LEESNITZER LM et al.: Identification of a series of PPARgamma/delta dual agonists via solid-phase parallel synthesis. Bioorg. Med. Chem. Lett. (2001) 11(22):2959–2962.
   PubMed Web of Science ®Google Scholar
• HDL Cholesterol. Second Annual Meeting, Metabolic Pathways and Drug Development, Boston, MA, USA (2001).
   Google Scholar
• BERGMAN JP, HAN W, METZGER E et al.: Discovery of novel arylthiazolidinedione derivatives as selective PPARgamma agonists for the treatment of Type II diabetes mellitus. 221st American Chemical Socieo, National Meeting, San Diego, CA, USA (2001):MEDI 240.
   Google Scholar
• BOUERES JK, HAN W, SANTINI C et al.: Novel class of aryl thiazolidinedione PPAR agonists as insulin sensitizing agents for the treatment of Type II diabetes mellitus. 221st American Chemical Society National Meeting, San Diego, CA, USA (2001):MEDI 241.
   Google Scholar
• ZEILLER JJ, BRUNET M, BERTELON JJ et al.: LR90, A new compound with both hypolipidemic and hypoglycemic activities. 220th American Chemical Socieo, National Meeting, Washington DC, USA (2000):MEDI 308.
   Google Scholar
• MURAKAMI K, TUBE K, IDE T et al: A novel sensitizer acts as a coling for perwdsome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma. Effects of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker Fatty rats. Diabetes (1998) 47(12):1841–1847.
   Google Scholar
• WULFF EM, JEPPESEN L, BURY PS et al.: Characterisation of a future generation insulin sensitizers M vitro and in vivo. Diabetes (2001) 50\(Suppl. 6):2210.
   Google Scholar
• IDE T, MURAKAMI K, TSUNODA M, MOCHIZUKI T, KADOWAKI T: KRP-297 improves impaired fatty acid oxidation in skeletal muscles and livers of Zucker diabetic fatty rats. Diabetologia (1999) 42\(Suppl. 1):50.
   Google Scholar
• MERCK & CO.: Annual report 1999 (March 07, 2000).
   Google Scholar
• LIGAND PHARMACEUTICALS, INC.: Company presentation (2001).
   Google Scholar
• BROOKS DA, ETGEN GJ, RITO CJ et al.: Design and synthesis of 2-methy1-2-[4-(2-[5-methy1-2-aryloxazol-4-yl] ethoxy)phenoxylpropionic acids: a new class of dual PPARalpha/gamma agonists. J. Med. Chem. (2001) 44(13):2061–2064.
   PubMed Web of Science ®Google Scholar
• SORBERA LA, CASTANER M, SILVESTRE J: Netoglitazone. Drugs Future (2002) 27(2): 132–129.
   Web of Science ®Google Scholar
• ISHII S, WASAKI M, OHE T, UENO H, TANAKA H: MCC-555: A highly potent thiazolidinedione lacking hematological and cardiac side-effects. Diabetes (1996) 45\(Suppl. 2):141.
   Google Scholar
• UPTON R, WIDDOWSON PS, KADOWAKI S, WILLIAMS G: Improved insulin sensitivity in Zucker and ZDF rats following chronic treatment with novel thiazolidinedione MCC-555. Br. Pharmacol (1997) 122(Proc. Suppl.):149P.
   Google Scholar
• SAUERBERG P, PETTERSSON I, JEPPESEN L et al: Novel tricyclic-alkoxphenylpropionic acids: Dual PPAR/ agonists with hypolipidemic and antidiabetic activity. Med. Chem (2002) 45(4):789–804.
   Web of Science ®Google Scholar
• YANAGISAWA H, TAKAMURA M, YAMADA E et al.: Novel oximes having 5-benzy1-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship. Bioorg. Med. Chem. Lett. (2000) 10(4):373–375.
   PubMed Web of Science ®Google Scholar
• OGUCHI M, WADA K, HONMA H et al.: Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones. I Med. Chem. (2000) 43(16):3052–3066.
   PubMed Web of Science ®Google Scholar
• DELMAS EB, LASSALLE I, SARDON V et al.: Conception, synthesis and pharmacological evaluation of PPAR(s) gamma ligands. Drugs Future (2002) 27(Suppl. A):P491.
   Google Scholar
• DEL CASTILLO JC, MOURELLE M, HUGUET J, CABRE F: Synthesis and biological activity of novel thiazolidine-2,4-diones series with potent antihyperglycemic and antihyperlipidemic oral activities. Drugs Future (2002) 27(Suppl. A):P209.
   Google Scholar
• MUKHERJEE R, DAVIES PJ, CROMBIE DL et al: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (1997) 386:407–410.
   PubMed Web of Science ®Google Scholar
• MICHELLYS PY et al: RXR modulators.Design, synthesis and hypoglycaemic activity of new RXR-selective locked-dienoic acids. 223rd American Chemical Society National Meeting, Orlando, FL, USA (2002):MEDI 004.
   Google Scholar
• MILLER AB, LENHARD JM, XU HE et al.: Structure based design of a potent RXR agonist. 223rd American Chemical Society National Meeting, Orlando, FL, USA (2002):MEDI–006.
   Google Scholar
• VULIGONDA V, THATCHER SM, CHANDRARATNA RA: Enantioselective syntheses of potent retinoid X receptor ligands: Differential biological activities of individual antipodes. I Med. Chem. (2001) 44:2298–2303.
   PubMed Web of Science ®Google Scholar
• MURRAY A, HANSEN JB, CHRISTENSEN BV: A novel synthesis of 9-cis-retinoic acid tagretin analogues via Pauson-Khand or Heck reaction. Tetrahedron (2001) 57:7383–7390.
   Web of Science ®Google Scholar
• OKU A, UETA K, ARAKAWA K et al.: Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats. Biol. Pharm. Bull. (2000) 23:1434–1437.
   PubMed Web of Science ®Google Scholar
• CHEN X, CONWAY BR, ERICKSON E, DEMAREST KT: RWJ394718 (T-1095), an inhibitor of sodium-glucose cotransporters increases urinary glucose excretion in Zucker diabetic fatty (ZDF) rats. Diabetes (2001) 50\(Suppl. 2):2153.
   Google Scholar
• JENS J, DEACON CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 diabetes. Diabetes (1998) 47: 1663-1670.
   Google Scholar
• ••An excellent review on the inhibition ofDPP-IV for the treatment of NIDDM.
   Google Scholar
• VILLHAUER EB, BRINKMAN JA, NADERI GB et al.:1- [2-[(5-Cyanopyridin-2-y0 amino] ethylamino] acety-2- (5) - pyrrolidine-carbonitrile: A potent, selective, and orally bioavailable dipeptidyl peptidase IV Inhibitor with antihyperglycemic properties. J. Med. Chem. (2002) 45:2362–2365.
   PubMed Web of Science ®Google Scholar
• HOLMES D: DPP-IV inhibitors and Type 2 diabetes. SMi Conference - Diabetes (2002).
   Google Scholar
• AHRN B, SIMONSSON E, EFENDIC J et al.: Inhibition of DPP-IV by NVP-DPP-728 improves metabolic control over a 4 week period in Type 2 diabetes. Diabetes (2001) 50\(Suppl. 1):416.
   Google Scholar
• ROTHENBERG P, KALBAG J, SMITH H, GINGERICH R, NEDELMAN J: Treatment with a DPP-IV inhibitor, NVP-DPP-728, increases prandial intact GLP-1 levels and reduces glucose exposure in humans. Diabetes (2000) 49\(Suppl. 1):39.
   Google Scholar
• NOVARTIS R&D DAY: Company presentation (2001).
   Google Scholar
• NOVARTIS R&D DAY: Company presentation (2002).
   Google Scholar
• FREYSE E, BERG S, HEINKE P et al.: Glucose metabolism in diabetic zucker fatty rats (ZR) during chronic oral therapy by the DP IV inhibitor P32/98. Diabetes (2000) 49\(Suppl. 1):1808.
   Google Scholar
• DEMUTH H, HOFFMAN T, GLUND K et al.: Single dose treatment of diabetic patients by the DP IV inhibitor P32/98. Diabetes (2000) 49\(Suppl. 1):413.
   Google Scholar
• DEMUTH H, HOFFMAN T, GLUND K et al.: Single dose treatment of diabetic patients by DP IV inhibitor P32/98. Diabetes (2000) 49\(Suppl. 1).
   Google Scholar
• GLUND K, HOFFMAN T, DEMUTH H et al.: Single dose-escalation study to investigate the safety and tolerability of the DP IV inhibitor P32/98. Diabetes (2000) 49\(Suppl. 1).
   Google Scholar
• DEMUTH H: Development of PS32/98. SMi Conference - Diabetes (2002).
   Google Scholar
• SUDRE B, BROQUA P, WHITE RB et al: Chronic inhibition of circulating dipeptidyl peptidase IV by FE-999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes (2002) 51:1461–1469.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA T et al: 22nd Symposium Medicinal Chemistry Shizuoka, Japan (2002) (Abstract 2P–06).
   Google Scholar
• KANSTRUP A, BRANNER S, CARR RD, CHRISTIANSEN LB, ELM T, RIBEL U: A structurally novel dipeptidyl peptidase IV inhibitor: 7-Benzy1-1,3-dimethy1-8-piperazinoxanthine. 28th National Medicinal Chemistry Symposium, San Diego, CA, USA (2002).
   Google Scholar
• TREADWAY JL, MENDYS P, HOOVER DJ: Glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes mellitus. Expert Opin. Investig. Drugs (2001) 10(3):439–454.
   PubMed Web of Science ®Google Scholar
• ••An outstanding review on the use of GSKinhibitors for the treatment of NIDDM.
   Google Scholar
• HOOVER DJ, MARTIN WH, TREAD WAY JL et al.: Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. Med. Chem (1998) 41:2934–2938.
   Google Scholar
• LUNDBECK JM, JAKOBSEN P, KRISTIANSEN M, WESTERGAARD N, ANDERSEN B, IVERSEN L: Novel [2-(benzoylamino)-phenoxy]-phthalic acid derivatives as potent hepatic glycogen phosphorylase inhibitors. 17th International Symposium on Medicinal Chemistry Barcelona, Spain (2002): P347.
   Google Scholar
• BERGANS N, STALMANS W, GOLMANN S, VANSTAPEL F: Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401: inhibition and inactivation of glycogen phosphorylase by an activated metabolite. Diabetes (2000) 49(9):1419–1426.
   PubMed Web of Science ®Google Scholar
• EVANS JL, BAHIJA J: Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Expert Opin. Investig. Drugs (1999) 8(2):139–160.
   PubMedGoogle Scholar
• BLASKOVICH MA, KIM HO: Recent discovery and development of protein tyrosine phosphatase inhibitors. Expert Opin. Ther. Patents (2002) 12(6):871–905.
   Web of Science ®Google Scholar
• ••A detailed review on PTP-1B inhibitors.
   Google Scholar
• HANSEN TK, IVERSON LF, LAU J et al: Potent non-peptide protein-tyrosine phosphatase inhibitors. 223rd American Chemical Society National Meeting, Orlando, FL, USA (2002): MEDI 003.
   Google Scholar
• ANDERSON HS, OLSEN OH, IVERSON LF et al.: Discovery and SAR of a novel selective and orally bioavailable non-peptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. Med. Chem. (2002) 45(20):4443–4459.
   Web of Science ®Google Scholar
• PEI Z: 61st American Diabetes Association - Scientific Sessions, Philadelphia, PA, USA (2001).
   Google Scholar
• PEI Z, ZINKER BA, GUM RJ et al: (2R)-2- (2',6'-dichloro-4'-dibenzo (b,d)furan-4'-ylphenoxy)-3-phenylpropanoic acid (A-321842) as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with anti-diabetic effects in ob/ob mice. Diabetes (2001) 50\(Suppl. 6):1524.
   Google Scholar
• MALAMAS MS, SREDY J, GUNAWAN I et al.: New azolidinediones as inhibitors of protein tyrosin phosphatase 1B with antihyperglycemic properties. I Med. Chem. (2000) 43(5):995–1010.
   PubMed Web of Science ®Google Scholar
• MALAMAS MS, SREDY J, MOXHAM C et al.: Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. .1. Med. Chem. (2000) 43(7):1293–1310.
   Google Scholar
• KAIDANOVICH 0, ELDAR-FINKELMAN H: The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes. Expert Opin. Tiler. Targets (2002) 6(5):555–561.
   PubMedGoogle Scholar
• MARTINEZ A, CASTRO A, DORRONSORO I, ALONSO M: Glycogen synthase kinase 3 (GSK 3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. (2002) 22(4):373–384.
   PubMed Web of Science ®Google Scholar
• ••An up-to-date review on GSK-3 inhibitors.
   Google Scholar
• HENRIKSEN EJ, JOHNSON KW, KINNICK TR, O'KEEFE MP, HARRISON SD: Oral treatment of glycogen synthase kinase-3 inhibitor improves glucose tolerance and skeletal muscle glucose transport activity in zucker diabetic fatty rats. Diabetologia (2001) 44\(Suppl. 1):681.
   Google Scholar
• CLINE GW, JOHNSON K, REGITTNIG W et al.: Effects of a novel glycogen synthase kinse-3 inhibitor on insulin stimulated glucose metabolism in ZDF (fa/fa) rats. Diabetes (2002) 50(2):1281.
   Google Scholar
• CLINE GW, JOHNSON K, REGITTNIG W, PERRET P: Effects of novel glycogen synthase-3 (GSK-3) inhibitor on liver and muscle glycogen synthesis in awake ZDF (fa/fa) diabetic rat. Diabetes (2001) 51\(Suppl. 6):1350.
   Google Scholar
• SAMUELS I, LOW C, FAWCETT K et al: Efficacy and pharmacological properties of novel glycogen synthase kinase-3 (GSK-3) inhibitors in rodent models of Type 2 diabetes. Diabetes (2001) 50\(Suppl. 6):1352.
   Google Scholar
• BOWLER AN, KILBURN JP, ENGLEHARDT S, DANIELSEN GM, KURTZHALS P: Novel substituted oxadiazepines with glucose lowering properties. 16th International Symposium of Medicinal Chemistry Bologna, Italy (2000):PA 9.
   Google Scholar
• Novo Nordisk A/S. Drug report of GSK-3 inhibitors. IDdb.? report (2002).
   Google Scholar
• HAIGH D et al.: 12th Symposium on Medicinal Chemistry Hatfield, UK (2001).
   Google Scholar
• COUGHLAN MP, CULBERT AA, CROSS DAE et al.: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. (2000) 7(10):793–803.
   PubMed Web of Science ®Google Scholar